At the news
? BULLISHIMPACT 6/10 8-K filed Jul 30, 2026 at 16:01 ET
Keros Therapeutics announced a $20 million development milestone payment from partner Takeda triggered by dosing the first patient in the Phase 3 ELRiSE MDS trial for elritercept. The company expects to distribute 25% of the net cash proceeds from this milestone to stockholders, providing a tangible near-term capital return catalyst.
- $20 million development milestone payment from Takeda triggered by first patient dosed in Phase 3 ELRiSE MDS trial
- Phase 3 trial (ELRiSE MDS) is a multicenter, open-label, randomized study comparing elritercept vs epoetin alfa in low-risk MDS
- Keros expects to distribute 25% of net cash proceeds from this milestone to stockholders
- Under the global license agreement (effective Jan 16, 2025), Keros received $200M upfront in Feb 2025 and is eligible for up to $1.1B+ in milestones plus tiered royalties
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access